What is it?
What is Tirzepatide?
Tirzepatide is a peptide-based dual agonist at the GIP and GLP-1 receptors. Unlike a GLP-1-only agonist, the molecule therefore addresses two related receptor systems.
Peptide Profile
Tirzepatide
Tirzepatide is a peptide-based dual agonist at the GIP and GLP-1 receptors. Unlike a GLP-1-only agonist, the molecule therefore addresses two related receptor systems.
GIP + GLP-1Approved medicinesPhase 3 evidenceFDAPubMed
Receptor profile
GIP + GLP-1
Tirzepatide selectively binds to and activates both GIP and GLP-1 receptors. The combination of these two receptor targets is the defining feature of the molecule.
Scientific status
Context
Tirzepatide is used in approved medicinal products. In a research catalogue it is therefore important to distinguish the described molecule or research material from an approved medicinal product.
Peptide analytics
Documentation instead of generic claims.
Documentation should link the specific batch to the analytical records actually available. For peptides, identity and purity data can for example be documented using LC-MS and HPLC when those tests exist for the relevant batch.
References & studies
Sources directly related to this peptide.
Official references and selected peer-reviewed studies. Study links are provided for scientific context and are not administration guidance.
Official reference
FDA · ZEPBOUND Prescribing Information
U.S. FDA · 2026Reference for regulatory status, product information and the combined GIP/GLP-1 receptor profile.
Open source ↗Clinical studySURMOUNT-1 · Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff et al. · N Engl J Med · 2022 · PMID 35658024Randomized phase 3 trial in adults with obesity or overweight without diabetes.
Open source ↗Comparative studySURPASS-2 · Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías et al. · N Engl J Med · 2021 · PMID 34170647Randomized comparative trial in adults with type 2 diabetes.
Open source ↗